Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Behavioral Neurology & Neuropsychiatry
Is there a known washout period for Leqembi/Kisunla?
Related Questions
What is your approach to patients who develop ARIA-E or ARIA-H during treatment with anti-amyloid therapies?
Do you get volumetric MRI in all patients with cognitive difficulties?
How do you treat extrapyramidal symptoms secondary to anti-psychotic use in patients who have not benefited from cogentin or benadryl?
What would prompt discontinuing treatment versus switching or sequencing treatment in patients treated with an anti-amyloid therapy for Alzheimer's?
Do you use amyloid lowering therapy in patients on chronic anticoagulation?
How would you manage cognitive changes in a patient with memory impairment and significant brain atrophy with no diagnostic testing consistent with Alzheimer's disease?
Is the p-tau217 plasma test used as a surrogate for amyloid PET scan or CSF testing when considering starting Leqembi in patients with Alzheimer's disease?
Is a history of coronary artery disease and afib a contraindication to using donepezil?
How do you approach an isolated increased protein levels in the CSF in patients with cognitive decline?
What is the minimum level of cognitive symptoms that would prompt you to pursue biomarker testing required for anti-amyloid therapies for Alzheimer's?
